In Vitro Data, Broad Dosage Ranges Fail to Enable Patient-Treatment Claims

Short summary

The Federal Circuit affirmed invalidation of Wyeth's EGFR inhibitor treatment patents for lack of enablement, holding that in vitro data and broad dosage ranges (1-1,000 mg) did not teach a workable human-dosing regimen. The Court found claims requiring daily patient administration demanded more than compound identification, and toxicity evidence showed disclosed dosages exceeded maximum tolerated doses. The decision clarifies that treatment claims need sufficient guidance for clinical translation without requiring FDA-grade proof.

• •Federal Circuit affirmed Wyeth treatment patents invalid for lack of enablement
• •In vitro data and broad dosage ranges insufficient to teach workable human dosing regimen
• •Claims requiring daily patient administration demand more than compound identification alone

Generated with AI, which can make mistakes.